Gutiérrez-López C, Plascencia-Álvarez N, Quiñones-Aguilar S, Toriz-Ortiz A, Núñez-Orozco L

Language: Spanish
References: 20
Page: 438-444
PDF size: 76.07 Kb.

ABSTRACT

Introduction: The frequency of nephrolythiasis in the general population is 1 to 10%. Some publications report that topiramate increases the risk for nephrolythiasis, reason because we decided to study this relationship in a group of patients with refractory epilepsy in treatment with polytherapy with or without topiramate. Material and methods: We found nephrolythiasis in 60% of patients with topiramate and other antiepileptic drugs and 43.5% with other antiepileptic drugs without topiramate. Results: The Odd Ratio is 2.9 times for the topiramate group comparing to the group without it, to ponder with risk factors. In both groups we find higher frequency of nephrolythiasis than in the general population. The main risk factor for the development of nephrolythiasis is to suffer refractory epilepsy because it favours polytherapy and the chronic use of antiepileptic drugs, which produce metabolic alterations that lead to a secondary hyperparathyroidism. Conclusion: The percentage of nephrolythiasis found in both groups is significantly higher than in the general population, specially with topiramate because of its inhibitory action on carbonic anhydrase.

REFERENCES

1. Glausser TA. Topiramate. Epilepsia 1999: 40(Suppl. 5): S71-80.

2. Herranz JL. Datos actuales sobre topiramato. Rev neurol 2000; 30(Suppl. 1): S132-S136.

3. Brian J. Biochemical and Stone Risk profiles with Topiramate treatment. American Journal of Kidney Disease 2005; 45(2): 422-8.

4. Lhatoo. The safety and adverse event profile of topiramate Rev. Contemp pharmacother 1999; 10: 180-91.

5. Alarcón M, et al. Topiramato y nefrolitiasis. Rev Neurol 2006; 42(2): 91-4.

6. Welch BJ, et al. Biochemical and stone profiles with topiramate treatment. American Journal of Kidney Diseases 2006; 48(4): 555-63.

7. Sheth RD. Metabolic concerns associated with antiepleptics medications. Neurology 2004; 63(Suppl. 4): S24-S29.

8. Nieto B. Características e indicaciones del topiramato. Rev Neurol 2002; 35(Suppl. 1): S88-S95.

9. Medina M, Zaidi M. Prevalencia y factores de riesgo en Yucatán, México para litiasis urinaria. Sal Púb Méx 2002; 44(6): 541-5.

10. Piñero R, Rodríguez M. Litiasis renal en la consulta de atención primaria. Monografía Madrid 2003; 2(5): 1-12.

11. Bihl G, Meyers A. Recurrent renal stone disease advantages in patogénesis and clinical management. The Lancet 2001; 651-656p.

12. Kiriaki K, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Vol. 63. Kidney International; 2003, p. 1817-23.

13. Amato M, et al. Title epidemiology of nephrolithiasis today. Source Urologia Internationalis 2004; 72(Suppl. 1): 1-5.

14. Ramello A, et al. The epidemiology of nephrolithiasis. Source Journal of Nephrology 2000; 13(Suppl. 3): 45-50.

15. Curhan C, Rimm E, Willet W, Stampfer M. Regional variation in nephrolithiasis incidence and prevalence among Unite States men. J Urol 1994; 151: 838-41.

16. Otero F, Lugo A, Durán A. Las enfermedades renales en el Instituto Mexicano del Seguro Social (1982-1989). Rev Asoc Med Int Mex 1995; 11; 21-9.

17. World Health Organization, Guidelines for drinking water Anuality. Vol. 1. Recommendations, Ginebra: WHO; 1993.

18. Marván L. Sistema mexicano de alimentación y equivalentes. 2a. Ed. First.

19. North EpilepsyC: 60th annual meeting of American epilepsy society.

20. Gross RA, et al. Antiseizure drugs and reduced bone density. Neurology 2004; 62; 24-5.